Oruka Therapeutics: How This Small Name Is Rivaling AbbVie's $18 Billion Franchise
Investor's Business Daily • • business
Key Points:
- Investor’s Business Daily (IBD) provides information solely for educational and informational purposes and does not offer investment advice or solicitations to buy or sell securities.
- The data presented is sourced from what IBD believes are reliable providers, but no guarantees are made regarding its accuracy, timeliness, or suitability.
- Past investment performance shared by IBD does not predict or ensure future results, and authors may hold positions in the stocks they discuss.
- IBD disclaims any warranties about the advisability of specific investments or strategies, and information is subject to change without prior notice.
- Real-time pricing is provided by Nasdaq Last Sale, with ownership and estimate data from LSEG and FactSet, and all trademarks are owned by Investor’s Business Daily, LLC.
